Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old
- PMID: 17062862
- DOI: 10.1001/jama.296.16.1990
Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old
Abstract
Context: Beginning with the winter season of 2004-2005, influenza vaccination has been recommended for all children 6 to 23 months old in the United States. However, its safety in young children has not been adequately studied in large populations.
Objective: To screen for medically attended events in the clinic, emergency department, or hospital after administration of trivalent inactivated influenza vaccine in children 6 to 23 months old.
Design, setting, and participants: Retrospective cohort using self-control analysis, with chart review of significant medically attended events at 8 managed care organizations in the United States that comprise the Vaccine Safety Datalink. Participants were all children in the Vaccine Safety Datalink cohort 6 to 23 months old who received trivalent inactivated influenza vaccine between January 1, 1991, and May 31, 2003 (45,356 children with 69,359 vaccinations).
Main outcome measure: Any medically attended event significantly associated with trivalent inactivated influenza vaccine in risk windows 0 to 3 days, 1 to 14 days (primary analysis), 1 to 42 days, or 15 to 42 days after vaccination, compared with 2 control periods, one before vaccination and the second after the risk window. All individual ICD-9 codes as well as predefined aggregate codes were examined.
Results: Before chart review, only 1 diagnosis, gastritis/duodenitis, was more likely to occur in the 14 days after trivalent inactivated influenza vaccine (matched odds ratio [OR], 5.50; 95% confidence interval [CI], 1.22-24.81 for control period 1, and matched OR, 4.33; 95% CI, 1.23-15.21 for control period 2). Thirteen medically attended events were less likely to occur after trivalent inactivated influenza vaccine, including acute upper respiratory tract infection, asthma, bronchiolitis, and otitis media. After chart review, gastritis/duodenitis was not significantly associated with trivalent inactivated influenza vaccine (matched OR, 4.00; 95% CI, 0.85-18.84 for control period 1; matched OR, 3.34; 95% CI, 0.92-12.11 for control period 2).
Conclusions: In the largest population-based study to date of the safety of trivalent inactivated influenza vaccine in young children, there were very few medically attended events, none of which were serious, significantly associated with the vaccine. This study provides additional evidence supporting the safety of universally immunizing all children 6 to 23 months old with influenza vaccine.
Similar articles
-
Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink.Arch Pediatr Adolesc Med. 2011 Aug;165(8):749-55. doi: 10.1001/archpediatrics.2011.112. Arch Pediatr Adolesc Med. 2011. PMID: 21810637
-
Safety of the trivalent inactivated influenza vaccine among children: a population-based study.Arch Pediatr Adolesc Med. 2004 Nov;158(11):1031-6. doi: 10.1001/archpedi.158.11.1031. Arch Pediatr Adolesc Med. 2004. PMID: 15520339
-
Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial.Pediatrics. 2005 Sep;116(3):e397-407. doi: 10.1542/peds.2004-2258. Pediatrics. 2005. PMID: 16140685 Free PMC article. Clinical Trial.
-
Adverse Events Following Trivalent Inactivated Influenza Vaccination in Children: Analysis of the Vaccine Adverse Event Reporting System.Pediatr Infect Dis J. 2011 Jan;30(1):e1-8. doi: 10.1097/INF.0b013e3181ff9795. Pediatr Infect Dis J. 2011. PMID: 21042229 Review.
-
Bilateral deafness two days following influenza vaccination: a case report.Hum Vaccin Immunother. 2019;15(1):107-108. doi: 10.1080/21645515.2018.1509657. Epub 2018 Sep 5. Hum Vaccin Immunother. 2019. PMID: 30118641 Free PMC article. Review.
Cited by
-
Examining the Negative Sentiments Related to Influenza Vaccination from 2017 to 2022: An Unsupervised Deep Learning Analysis of 261,613 Twitter Posts.Vaccines (Basel). 2023 May 23;11(6):1018. doi: 10.3390/vaccines11061018. Vaccines (Basel). 2023. PMID: 37376407 Free PMC article.
-
Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review.BMJ Glob Health. 2019 Jul 8;4(4):e001065. doi: 10.1136/bmjgh-2018-001065. eCollection 2019. BMJ Glob Health. 2019. PMID: 31354969 Free PMC article.
-
Emerging Challenges and Opportunities in Infectious Disease Epidemiology.Am J Epidemiol. 2019 May 1;188(5):873-882. doi: 10.1093/aje/kwy264. Am J Epidemiol. 2019. PMID: 30877295 Free PMC article. Review.
-
Burden, effectiveness and safety of influenza vaccines in elderly, paediatric and pregnant populations.Ther Adv Vaccines Immunother. 2019 Feb 7;7:2515135519826481. doi: 10.1177/2515135519826481. eCollection 2019. Ther Adv Vaccines Immunother. 2019. PMID: 30793097 Free PMC article. Review.
-
[The universal influenza vaccination in children with Vaxigrip Tetra® in Italy: an evaluation of Health Technology Assessment].J Prev Med Hyg. 2018 May 30;59(1 Suppl 1):E1-E86. eCollection 2018 May. J Prev Med Hyg. 2018. PMID: 30465031 Free PMC article. Italian. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
